4-Ethyl-1-methyl-2-propyl-pyrrolidin | 1497-93-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 4-Ethyl-1-methyl-2-propyl-pyrrolidin
• 英文别名: 4-ethyl-1-methyl-2-propyl-pyrrolidine；1-Methyl-4-ethyl-2-n-propylpyrrolidine；4-ethyl-1-methyl-2-propylpyrrolidine
• CAS: 1497-93-4
• 化学式: C₁₀H₂₁N
• 分子量: 155.283
• InChiKey: IJYIHQGNGBFGDH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• NITRIC OXIDE RELEASING STEROIDS
  申请人：Benedini Francesca

  公开号：US20100093685A1

  公开（公告）日：2010-04-15

  The invention relates to nitrooxyderivative of corticosteroids of general formula (I) and pharmaceutically acceptable salts or stereoisomers thereof R-(Z) a -R x (I) wherein R is the corticosteroid residue of formula (II): wherein: R 1 is OH, R 2 —CH 3 , or R 1 and R 2 are taken together to form a group of formula (III) R 3 is Cl or F; R 4 is H or F; wherein R 1 , R 2 , R 3 and R 4 can be linked to the correspondent carbon atoms of the steroidal structure in position α or β; with the proviso that: when R 1 and R 2 are the group of formula (III) then R 3 is F and R 4 is H or F; The compounds are useful in the treatment of respiratory diseases, inflammatory diseases, dermatological diseases and ocular diseases.

  本发明涉及一般式（I）的皮质类固醇的硝酰氧衍生物及其药学上可接受的盐或立体异构体： R-(Z)a-Rx(I) 其中，R是公式（II）的皮质类固醇残基： 其中： R1是OH，R2是CH3，或者R1和R2结合形成公式（III）的基团； R3是Cl或F； R4是H或F； 其中，R1、R2、R3和R4可以与类固醇结构中的相应碳原子在α或β位置相连； 但是，当R1和R2是公式（III）的基团时，R3是F，R4是H或F； 这些化合物在治疗呼吸系统疾病、炎症性疾病、皮肤病和眼科疾病方面具有用途。
• Methods and compositions for treating neurological disease
  申请人：Manoharan Muthiah

  公开号：US20070105803A1

  公开（公告）日：2007-05-10

  This invention relates to methods and compositions for treating neurological disease, and more particularly to methods of delivering iRNA agents to neural cells for the treatment of neurological diseases.
• METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE
  申请人：ARONIN NEIL

  公开号：US20100267810A1

  公开（公告）日：2010-10-21

  This invention relates to methods and compositions for treating neurological disease, and more particularly to methods of delivering iRNA agents to neural cells for the treatment of neurological diseases.
• US7582744B2
  申请人：——

  公开号：US7582744B2

  公开（公告）日：2009-09-01